Abstract: Provided is a fusion protein dimer using an antibody Fc region as the backbone, comprising a first and a second polypeptide chain. The first polypeptide chain comprises a first antibody Fc region and one or more single-domain antibodies fused to the first antibody Fc region. The second polypeptide chain comprises a second antibody Fc region and one or more single domain antibodies fused to the second antibody Fc region. The first polypeptide chain and/or the second polypeptide chain further comprise a cytokine fused to the Fc region of the respective antibody. Further provided is use of the fusion protein dimer in preparing an immunotherapeutic drug for treating tumors. The Fc fusion protein heterodimer not only increases the activity of a single domain antibody, but also significantly improves the biological activity of a cytokine.

Abstract: A sample processing apparatus (100) and a use method therefor. The sample processing apparatus (100) comprises a uniform mixing mechanism (130) and a magnetic attraction mechanism (140). The sample processing apparatus (100) further comprises at least one of a sample tube (110) and a reaction tube (120). The uniform mixing mechanism (130) is configured to perform uniform mixing processing on a biological sample in the sample tube (110) and/or a biological sample in the reaction tube (120). The magnetic attraction mechanism (140) comprises a magnet (141). The magnet (141) can move relative to the sample tube (110) and/or the reaction tube (120), so as to perform magnetic attraction processing on the biological sample in the sample tube (110) and/or the biological sample in the reaction tube (120).

Abstract: An automatic extraction device and a use method therefor. The automatic extraction device comprises a sample processing apparatus (100), a portal frame (200), a consumable assembly (300), and a pipetting apparatus (400). The sample processing apparatus (100) comprises a uniform mixing mechanism (130) and a magnetic attraction mechanism (140), which are respectively used for performing uniform mixing processing and magnetic attraction processing on a biological sample. The portal frame (200) comprises a base (201) and a moving beam (202) capable of moving relative to the base (201). The sample processing apparatus (100) and the consumable assembly (300) are provided on the base (201). The pipetting apparatus (400) is provided on the moving beam (202) for implementing a pipetting operation between the consumable assembly (300) and the sample processing apparatus (100).

Abstract: A capillary clip, a capillary electrophoresis apparatus, and a method for using a capillary clip. The capillary clip comprises a clip body, and a refrigerant channel, and at least two capillary channels defined by the clip body. The clip body comprises an inlet segment clip portion (100), a detection portion (200), and an outlet combination portion (300), wherein the inlet segment clip portion (100), the detection portion (200) and the outlet combination portion (300) are detachably connected in sequence in a sealed manner. The refrigerant channel and each capillary channel are combined at the inlet segment clip portion (100) and the outlet combination portion (300), and the refrigerant channel and each capillary channel are separated at a detection window (201) of the detection portion (200). A capillary (700) can be mounted in the capillary channel.

Abstract: An optical element detachable capillary clip and a capillary electrophoresis apparatus. The capillary clip comprises at least one capillary channel and a clip body defining the at least one capillary channel, and a capillary (700) can be mounted in the capillary channel. The clip body is provided with a detection window (201) and at least one optical detection element, the at least one optical detection element being directly or indirectly connected in the detection window (201). The at least one optical detection element can be removed from the clip body, such that the detection window (201) exposes at least part of an unobstructed region.

Abstract: An isolated antibody, or an antigen-binding portion thereof, targeting Claudin 18.2. The antibody can be single domain antibody, or its monomeric variable domain can be fused with a heavy chain constant region, such as a human IgG1 Fc. Pharmaceutical compositions including the antibody, and methods of use of the pharmaceutical compositions in the treatment of diseases are also provided.

Abstract: A blending tube (10), comprising: a tube body (20), the tube body (20) being used for accommodating a sample; and a first stirring member (30) and a second stirring member (40), which are arranged on an inner wall (200) of the tube body (20), wherein a width-to-thickness ratio of the first stirring member (30) is greater than a width-to-thickness ratio of the second stirring member (40).

Abstract: Provided is an automated system for preparing purified plasmid DNA in commercial scale.

Abstract: The invention relates to an antibody or an antigen-binding portion thereof that specifically binds to Ang2, blocking Ang2 binding to Tie2 or integrins, or triggering Ang2 clusting and Tie2 signaling activation.

Abstract: The present invention relates to the field of biochips, and provides a surface linker for a semiconductor chip, a preparation method therefor and an application thereof. The chip surface linker reacts with a chip surface by means of using silanized molecules as a solute and toluene as a solvent so as to form bonding molecules connected to the chip surface, and is prepared by reacting with functionalized molecules to modify a hydroxyl group and an ester group. The chip surface linker obtained by the present invention may be stably bonded to the chip surface, is stable under acidic and alkaline conditions, has good electrical conductivity, electrical stability and resistance to organic solvents required for nucleic acid synthesis, and is extremely advantageous for subsequent nucleic acid.

Abstract: The present invention relates to the field of biochips, and provides a chip surface linker and a preparation method and a use therefor. The chip surface linker is obtained by means of applying a direct current voltage to an aromatic amine bonding molecule in the presence of an acid and a nitrite to cause a reaction with a chip surface to form a bonding molecular group connected the chip surface, and then using a functional molecular for reaction and modification to add a functional molecular group containing a hydroxyl group and an ester group. The chip surface linker obtained in the present invention is able to bond more stably with a chip surface, being stable in hot water and basic conditions, and features relatively good electrical conductivity, stability during energization, and resistance to organic solvents required for nucleic acid synthesis, and is thus very advantageous for subsequent nucleic acid synthesis and other uses.

Abstract: The present application provides multispecific constructs that bind to Claudin-18.2 (such as various anti-Claudin-18.2×anti-PD-L1 bispecific antibodies), nucleic acids encoding the multispecific construct or a portion thereof, vectors comprising the nucleic acids, host cells containing the vectors, methods of preparing the multispecific constructs, pharmaceutical compositions comprising any of the multispecific constructs, and methods of using the multispecific constructs or compositions.

Abstract: The present application provides fusion proteins that have a TGF? superfamily receptor ectodomain (such as fusion proteins that have a TGF? superfamily receptor ectodomain and bind to PD-L1), nucleic acids encoding the fusion protein or a portion thereof, vectors comprising the nucleic acids, host cells containing the vectors, methods of preparing the fusion proteins, pharmaceutical compositions comprising any of the fusion proteins, and methods of using the fusion proteins or compositions.

Abstract: Anti-GITR antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases, such as cancer.

Abstract: Provided is a high-loading and alkali-resistant protein A magnetic bead. The magnetic bead can maintain chemical stability under pH 2-14 and has an immunoglobulin G (IgG) binding capacity greater than 50 mg/mL. Further provided is a method for purifying and/or detecting an immunoglobulin, comprising a step of contacting a sample containing the immunoglobulin with the high-loading and alkali-resistant protein A magnetic bead. The alkali-resistant protein A magnetic bead can realize rapid purification of immunoglobulin, saving about 80% of treatment time and reducing total purification costs by 50%. In addition, the alkali-resistant protein A magnetic bead has high alkali resistance. An alkaline method for in situ cleaning can be performed to regenerate the magnetic bead after use. The magnetic bead has rapid magnetic response and good dispersiveness, realizing rapid magnetic bead enrichment, cleaning, and elution.

Abstract: An oligonucleotide containing a blocker, relating to the field of target sequence hybridization capture and the design and synthesis of universal blocking oligonucleotides. Applying an oligonucleotide that has a blocking function or a combination thereof not only has a good blocking effect on an linker sequence during the capture of a target sequence in a single sample, but also reduces non-specific capture and improves the capture efficiency. In particular, the oligonucleotide may effectively block linker sequences at both ends of a target sequence in a plurality of samples and improve the target sequence capture efficiency.

Abstract: The present invention relates to an anti-CD47/anti-CTLA-4 bispecific antibody and a preparation method thereof and an application thereof. The bispecific antibody comprises (a) a first antigen-binding portion, comprising a heavy chain variable region (VH) and a light chain variable region (VL), where VH and VL form an antigen-binding site that specifically binds to CD47; and (b) a second antigen-binding portion comprising a single domain antibody (sdAb) that specifically binds to CTLA-4, the first antigen-binding portion and the second antigen-binding portion are fused to each other. The bispecific antibody to which the present invention relates may simultaneously block two means of tumor immune escape, and therefore has a better effect in tumor immunotherapy.

Abstract: The present invention relates to an anti-CD47/anti-PD-1 bispecific antibody, preparation method thereof and use thereof. The bispecific antibody includes (a) a first antigen binding portion including a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH and VL form an antigen binding site that specifically binds to CD47; and (b) a second antigen binding portion including a single-domain antibody (sdAb) that specifically binds to PD-1, wherein the first antigen binding portion and the second antigen binding portion are fused with each other. The bispecific antibody of the present invention can block two manners of tumor immune escape simultaneously, and thus, has a good effect in tumor immunotherapy.

Abstract: The present application provides multiple antigen binding proteins containing a first antigen binding portion that specifically binds an epitope on CD47, preferably human CD47, and a second antigen binding portion that specifically binds an epitope on programmed death-ligand 1 (PD-L1). Also provided are nucleic acids encoding the multiple antigen binding proteins, vectors comprising the nucleic acids, host cells comprising the vectors, and pharmaceutical compositions comprising the multiple antigen binding proteins, as well as methods for treating cancer using the multiple antigen binding proteins and pharmaceutical compositions.

Abstract: Anti-CD47/anti-TIGIT bispecific antibody, a preparation method thereof and application thereof. The bispecific antibody comprises: (a) a first antigen binding part, comprising heavy chain variable region (VH) and light chain variable region (VL), VH and VL forming an antigen binding site that specifically binds to CD47; and (b) a second antigen binding part, comprising a single domain antibody (sdAb) that specifically binds to TIGIT, wherein the first antigen binding part and the second antigen binding part are fused with each other. The bispecific antibody can block two modes of tumor immune escape at the same time, thus having a good effect in tumor immunotherapy.